Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3717 |
Name | gastric adenocarcinoma |
Definition | A stomach carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer stomach cancer stomach carcinoma gastric adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | Fluorouracil + PI-103 | gastric adenocarcinoma | sensitive | detail... |
FGFR2 amp | Fexagratinib | gastric adenocarcinoma | no benefit | detail... |
TP53 wild-type | Adavosertib + Radiotherapy | gastric adenocarcinoma | no benefit | detail... |
MSH6 negative | Ipilimumab + Nivolumab | gastric adenocarcinoma | sensitive | detail... |
MLH1 negative | Ipilimumab + Nivolumab | gastric adenocarcinoma | sensitive | detail... |
FGFR2 over exp | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin | gastric adenocarcinoma | predicted - sensitive | detail... |
KIT Q556_K558del | Imatinib | gastric adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00780494 | Phase II | Bevacizumab + Capecitabine + Carboplatin | Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma | Completed | USA | 0 |
NCT01191697 | Phase II | Bevacizumab + Trastuzumab Capecitabine + Oxaliplatin | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | Active, not recruiting | USA | 0 |
NCT01450696 | Phase III | Capecitabine + Cisplatin + Trastuzumab | HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer | Terminated | USA | TUR | POL | NZL | ITA | HUN | GBR | ESP | DEU | BRA | AUS | 14 |
NCT01526473 | Phase I | AVX901 | A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 | Completed | USA | 0 |
NCT01662869 | Phase III | Onartuzumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric) | Completed | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 11 |
NCT01747551 | Phase II | Aflibercept Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | Completed | USA | 0 |
NCT01774786 | Phase III | Pertuzumab Capecitabine + Cisplatin + Fluorouracil + Trastuzumab | A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer | Completed | USA | TUR | ROU | POL | NLD | ITA | HUN | HRV | FIN | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 14 |
NCT01774851 | Phase II | MM-111 + Paclitaxel + Trastuzumab Paclitaxel + Trastuzumab | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | Terminated | USA | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01896531 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ipatasertib | A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer | Completed | USA | ITA | GBR | FRA | ESP | DEU | 5 |
NCT01913639 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | Completed | USA | 0 |
NCT02016534 | Phase II | AMG 337 | Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors | Terminated | USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 4 |
NCT02024607 | Phase Ib/II | Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | Completed | USA | CAN | 0 |
NCT02065765 | Phase II | Ramucirumab | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | No longer available | NLD | GRC | DEU | AUT | 1 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02178956 | Phase III | Napabucasin Paclitaxel | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer | Completed | USA | ROU | POL | LTU | ITA | ISR | HUN | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | 4 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02205047 | Phase II | Capecitabine + Cisplatin Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Capecitabine + Cisplatin + Pertuzumab + Trastuzumab | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION) | Active, not recruiting | NOR | NLD | ITA | GBR | FRA | EST | ESP | DEU | CHE | BEL | 3 |
NCT02213289 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Docetaxel + Fluorouracil Trastuzumab Fluorouracil + Irinotecan + Leucovorin Rilotumumab | PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression | Completed | USA | 0 |
NCT02234596 | Phase II | Nintedanib | Nintedanib in Patients With Advanced Esophagogastric Cancer | Completed | USA | 0 |
NCT02241720 | Phase II | Regorafenib | Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers | Terminated | USA | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02283359 | Phase I | Irinotecan + Selinexor | Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus | Terminated | USA | 0 |
NCT02317991 | Phase II | Nab-paclitaxel + Ramucirumab | Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer | Completed | USA | 0 |
NCT02335411 | Phase II | Cisplatin + Fluorouracil + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059) | Completed | 0 | |
NCT02340975 | Phase Ib/II | Durvalumab Tremelimumab | A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma | Completed | USA | CAN | 4 |
NCT02443324 | Phase I | Pembrolizumab + Ramucirumab | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium | Completed | USA | GBR | FRA | ESP | DEU | 1 |
NCT02494583 | Phase III | Capecitabine Cisplatin + Fluorouracil Pembrolizumab | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | Completed | 0 | |
NCT02500043 | Phase III | Trifluridine-tipiracil hydrochloride | Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer | Completed | USA | TUR | ROU | POL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 4 |
NCT02509507 | Phase I | Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab | Completed | USA | POL | ESP | DEU | CHE | BEL | AUT | AUS | 1 |
NCT02514551 | Phase II | Paclitaxel Ramucirumab | A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer | Completed | USA | TUR | SWE | ITA | GRC | ESP | DEU | CZE | CAN | BEL | 1 |
NCT02545504 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Andecaliximab | GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | TUR | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BEL | AUS | 3 |
NCT02551055 | Phase I | Docetaxel Paclitaxel Alisertib Mivavotinib Serabelisib | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma | Terminated | USA | ESP | 0 |
NCT02563548 | Phase I | PEGPH20 + Pembrolizumab | Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab | Completed | USA | 0 |
NCT02564900 | Phase I | Trastuzumab deruxtecan | Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Completed | USA | 1 |
NCT02572687 | Phase I | Durvalumab + Ramucirumab | A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | Completed | USA | ITA | ISR | FRA | ESP | DEU | 2 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02578368 | Phase III | Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (FLOT5) | Completed | DEU | 0 |
NCT02597036 | Phase I | LY3127804 Ramucirumab | A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | GBR | ESP | 1 |
NCT02625610 | Phase III | Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Avelumab Capecitabine + Oxaliplatin | Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100) | Completed | USA | TUR | ROU | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 5 |
NCT02625623 | Phase III | Avelumab Paclitaxel Irinotecan | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Completed | USA | POL | ITA | FRA | ESP | DEU | CZE | BEL | AUS | 1 |
NCT02638909 | Phase II | Ceritinib | Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies | Terminated | USA | 0 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Unknown status | USA | 1 |
NCT02678182 | Phase II | Durvalumab Rucaparib Capecitabine Trastuzumab Capecitabine + Ramucirumab | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM) | Active, not recruiting | GBR | 0 |
NCT02689284 | Phase Ib/II | Margetuximab-cmkb + Pembrolizumab | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | Completed | USA | CAN | 3 |
NCT02715531 | Phase I | Capecitabine Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Gemcitabine + Nab-paclitaxel Atezolizumab + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Bevacizumab Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | Completed | USA | NZL | AUS | 4 |
NCT02773524 | Phase III | Regorafenib | A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (INTEGRATEII) | Unknown status | USA | NZL | CAN | AUS | 3 |
NCT02864381 | Phase II | Nivolumab Andecaliximab + Nivolumab | GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | BEL | AUS | 0 |
NCT02908451 | Phase I | AbGn-107 | A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer | Terminated | USA | 1 |
NCT02918162 | Phase II | Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab | Perioperative Chemo and Pembrolizumab in Gastric Cancer | Completed | USA | 0 |
NCT02934464 | Phase III | Paclitaxel + Ramucirumab Fluorouracil + Leucovorin + Oxaliplatin Capecitabine + Oxaliplatin | Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers (ARMANI) | Unknown status | ITA | 0 |
NCT02943603 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach | Withdrawn | USA | 0 |
NCT02954536 | Phase II | Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | Completed | USA | 0 |
NCT03042611 | Phase III | Rivoceranib | Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer | Completed | USA | ROU | POL | ITA | GBR | FRA | DEU | 5 |
NCT03064490 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED) | Completed | USA | 0 |
NCT03081143 | Phase II | Paclitaxel + Ramucirumab Fluorouracil + Irinotecan + Leucovorin + Ramucirumab | Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (RAMIRIS) | Recruiting | ITA | DEU | AUT | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03102320 | Phase I | Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) | Completed | USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS | 2 |
NCT03122548 | Phase II | CRS-207 + Pembrolizumab | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | Terminated | USA | 0 |
NCT03141034 | Phase II | Irinotecan + Ramucirumab | Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma | Completed | USA | 0 |
NCT03193918 | Phase I | Crenolanib + Paclitaxel + Ramucirumab | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma | Completed | USA | 0 |
NCT03196232 | Phase II | Epacadostat + Pembrolizumab | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | Completed | USA | 0 |
NCT03221400 | Phase Ib/II | STA-8666 | PEN-866 in Patients With Advanced Solid Malignancies | Unknown status | USA | 0 |
NCT03221426 | Phase III | Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Active, not recruiting | USA | POL | LVA | LTU | ITA | ISR | GBR | FRA | EST | DEU | CAN | BRA | BEL | 11 |
NCT03257163 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer | Recruiting | USA | 0 |
NCT03281369 | Phase Ib/II | Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Active, not recruiting | USA | ISR | GBR | ESP | AUS | 2 |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) | Recruiting | USA | GBR | AUS | 1 |
NCT03321630 | Phase II | Lenvatinib + Pembrolizumab | A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | Completed | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03368963 | Phase Ib/II | Liposomal irinotecan + Trifluridine-tipiracil hydrochloride | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | Recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Completed | USA | 0 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03421288 | Phase II | Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE) | Recruiting | DEU | CHE | 0 |
NCT03427814 | Phase III | Pamiparib | Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer | Completed | USA | POL | HUN | GBR | FRA | ESP | CZE | BEL | AUS | 7 |
NCT03488667 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT03504397 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin | A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight) | Active, not recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 8 |
NCT03505320 | Phase II | Zolbetuximab Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Pembrolizumab + Zolbetuximab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Zolbetuximab Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer (ILUSTRO) | Active, not recruiting | USA | ITA | FRA | 3 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Completed | USA | 0 |
NCT03539822 | Phase I | Cabozantinib + Durvalumab | Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) | Active, not recruiting | USA | 0 |
NCT03588039 | Phase I | Oraxol + Pembrolizumab | Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03590054 | Phase I | Abexinostat + Pembrolizumab | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | Completed | USA | 0 |
NCT03615326 | Phase III | Oxaliplatin + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Oxaliplatin + Pembrolizumab + Tegafur-gimeracil-oteracil Potassium + Trastuzumab Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | GBR | FRA | ESP | DEU | BRA | AUS | 7 |
NCT03627728 | Phase II | Regorafenib | Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer (a-MANTRA) | Unknown status | ITA | 0 |
NCT03641313 | Phase II | Berzosertib + Irinotecan | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |
NCT03653507 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Zolbetuximab | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW) | Active, not recruiting | USA | TUR | ROU | NLD | IRL | HRV | GRC | GBR | ESP | CAN | ARG | 7 |
NCT03666273 | Phase I | BAY1905254 BAY1905254 + Pembrolizumab | A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 | Completed | USA | 0 |
NCT03675737 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 14 |
NCT03686488 | Phase II | Ramucirumab + Trifluridine-tipiracil hydrochloride | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | Completed | USA | 0 |
NCT03694522 | Phase II | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) | Completed | USA | TUR | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 6 |
NCT03697304 | Phase II | Ezabenlimab Miptenalimab | Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. | Active, not recruiting | USA | GBR | CAN | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03735290 | Phase Ib/II | Pembrolizumab Intuvax + Pembrolizumab | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD) | Terminated | USA | 0 |
NCT03739801 | Phase Ib/II | Liposomal irinotecan + Ramucirumab | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Withdrawn | USA | 0 |
NCT03752398 | Phase I | Izuralimab | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Completed | USA | 0 |
NCT03760822 | Phase II | Paclitaxel + Ramucirumab Ramucirumab | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE) | Active, not recruiting | FRA | 0 |
NCT03776487 | Phase Ib/II | Fluorouracil + Oxaliplatin Nivolumab Ipilimumab + Nivolumab Fluorouracil + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer | Active, not recruiting | USA | 0 |
NCT03777657 | Phase III | Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | Completed | USA | TUR | POL | ITA | GBR | FRA | ESP | 6 |
NCT03783936 | Phase II | Avelumab + Trastuzumab Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | Completed | USA | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03840967 | Phase II | Niraparib | A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma | Terminated | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Completed | USA | 0 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
NCT03918499 | Phase Ib/II | Cyclophosphamide + IRX-2 + Pembrolizumab | IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer | Completed | USA | 0 |
NCT03954704 | Phase I | Fluorouracil + GS-1423 + Leucovorin + Oxaliplatin GS-1423 | Study of GS-1423 in Participants With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03959293 | Phase II | Durvalumab + Fluorouracil + Irinotecan + Leucovorin + Tremelimumab Durvalumab + Fluorouracil + Irinotecan + Leucovorin | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | Active, not recruiting | FRA | 0 |
NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
NCT03966118 | Phase II | Avelumab + Paclitaxel + Ramucirumab | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma (AIO-STO-0218) | Unknown status | DEU | 0 |
NCT03995017 | Phase Ib/II | Ramucirumab + Rucaparib Nivolumab + Ramucirumab + Rucaparib | Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) | Active, not recruiting | USA | 0 |
NCT03997448 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | Terminated | USA | 0 |
NCT04006262 | Phase II | Ipilimumab + Nivolumab | Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NEONIPIGA) | Recruiting | FRA | 0 |
NCT04007744 | Phase I | Pembrolizumab + Sonidegib | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04021108 | Phase II | Nivolumab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) | Active, not recruiting | USA | 0 |
NCT04029922 | Phase I | MT-5111 | Study of MT-5111 in HER2-positive Solid Tumors (MT-5111) | Terminated | USA | NZL | AUS | 0 |
NCT04032704 | Phase II | Ladiratuzumab vedotin | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Terminated | USA | ITA | GBR | AUS | 2 |
NCT04041310 | Phase I | GAd-209-FSP + MVA-209-FSP | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Active, not recruiting | USA | ITA | GBR | ESP | CAN | BEL | 0 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | GBR | 0 |
NCT04069273 | Phase II | Paclitaxel + Ramucirumab Paclitaxel + Pembrolizumab + Ramucirumab Pembrolizumab | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (SEQUEL) (SEQUEL) | Recruiting | USA | 0 |
NCT04074343 | Phase I | Irinotecan + Trifluridine-tipiracil hydrochloride | TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma | Completed | USA | 0 |
NCT04089904 | Phase II | Pembrolizumab | Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | Terminated | USA | 0 |
NCT04099641 | Phase II | Bavituximab + Pembrolizumab | An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients | Completed | USA | GBR | 2 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Suspended | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Completed | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04152499 | Phase Ib/II | SKB264 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264) | Recruiting | USA | TUR | CAN | 2 |
NCT04164979 | Phase II | Cabozantinib + Pembrolizumab | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Terminated | USA | AUS | 1 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04260191 | Phase I | AMG 910 | Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma | Terminated | USA | NLD | FRA | ESP | DEU | AUT | 3 |
NCT04276376 | Phase II | Atezolizumab + Rucaparib | Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) | Suspended | FRA | 0 |
NCT04363801 | Phase II | DKN-01 + Tislelizumab Capecitabine + DKN-01 + Oxaliplatin + Tislelizumab | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish) | Active, not recruiting | USA | DEU | 1 |
NCT04379596 | Phase II | Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Oxaliplatin + Trastuzumab Fluorouracil + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Durvalumab + Trastuzumab deruxtecan Fluorouracil + Oxaliplatin + Trastuzumab deruxtecan Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Oxaliplatin + Trastuzumab deruxtecan Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Durvalumab + Fluorouracil + Trastuzumab deruxtecan Capecitabine + Durvalumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + Pembrolizumab + Trastuzumab deruxtecan Capecitabine + Fluorouracil + MEDI5752 + Trastuzumab deruxtecan Capecitabine + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Cisplatin + Trastuzumab Trastuzumab deruxtecan | Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03) | Recruiting | USA | POL | NLD | ITA | GBR | ESP | DEU | CAN | BRA | 5 |
NCT04393298 | Phase Ib/II | UCB6114 Trifluridine-tipiracil hydrochloride + UCB6114 Fluorouracil + Leucovorin + Oxaliplatin + UCB6114 | A Study to Assess the Safety, Pharmacokinetics and Antitumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | Completed | USA | GBR | 0 |
NCT04404595 | Phase Ib/II | Satricabtagene autoleucel | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | Active, not recruiting | USA | CAN | 0 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Active, not recruiting | USA | 1 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Terminated | USA | ESP | 1 |
NCT04450732 | Phase I | GQ1001 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | Recruiting | USA | AUS | 1 |
NCT04499924 | Phase II | Paclitaxel + Ramucirumab + Trastuzumab + Tucatinib Paclitaxel + Ramucirumab + Tucatinib Paclitaxel + Ramucirumab | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer (MOUNTAINEER-02) | Completed | USA | GBR | CAN | AUS | 2 |
NCT04510285 | Phase II | Pembrolizumab + Trastuzumab | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection | Terminated | USA | 0 |
NCT04517747 | Phase 0 | Ramucirumab + Trifluridine-tipiracil hydrochloride | Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL) | Completed | DEU | 0 |
NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
NCT04579757 | Phase Ib/II | Surufatinib + Tislelizumab | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04592913 | Phase III | Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Docetaxel + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin | Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer | Active, not recruiting | USA | TUR | POL | NLD | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | ARG | 6 |
NCT04604132 | Phase Ib/II | Atezolizumab + Derazantinib Derazantinib + Paclitaxel + Ramucirumab Derazantinib Paclitaxel + Ramucirumab | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03) | Terminated | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 3 |
NCT04660760 | Phase II | Paclitaxel + Ramucirumab Ramucirumab + Trifluridine-tipiracil hydrochloride | Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04704934 | Phase III | Paclitaxel + Ramucirumab Trastuzumab deruxtecan | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Active, not recruiting | TUR | ROU | POL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DEU | BRA | BEL | ARG | 10 |
NCT04717375 | Phase Ib/II | BND-22 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | GBR | CAN | 0 |
NCT04735796 | Phase I | LM-102 | Study of LM-102 in Subjects in Advanced Tumors | Terminated | USA | 0 |
NCT04739202 | Phase II | Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST) | Unknown status | FRA | 0 |
NCT04757363 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + Regorafenib | A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer | Active, not recruiting | USA | 0 |
NCT04777994 | Phase I | ABBV-CLS-484 + unspecified PD-1 antibody ABBV-CLS-484 | A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | Recruiting | USA | ISR | FRA | ESP | 2 |
NCT04779151 | Phase II | Dostarlimab-gxly + Niraparib | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NIRADO) | Suspended | FRA | 0 |
NCT04798781 | Phase II | Pembrolizumab + Telatinib | Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT04834778 | Phase I | HC-5404-FU | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | Completed | USA | 0 |
NCT04879368 | Phase III | Docetaxel Paclitaxel Trifluridine-tipiracil hydrochloride Nivolumab + Regorafenib Irinotecan | RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) | Active, not recruiting | USA | ITA | ESP | DEU | AUT | AUS | 3 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05001516 | Phase Ib/II | TPX-4589 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | Completed | USA | 0 |
NCT05002127 | Phase II | Paclitaxel + Ramucirumab + Trastuzumab Paclitaxel + Ramucirumab Evorpacept + Paclitaxel + Ramucirumab + Trastuzumab | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | Recruiting | USA | ITA | GBR | FRA | ESP | CZE | BEL | AUS | 4 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05041153 | Phase I | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | Recruiting | USA | 0 |
NCT05052801 | Phase III | Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NOR | LVA | LTU | ITA | ISR | IRL | HUN | GRC | FRA | EST | ESP | DNK | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 13 |
NCT05070247 | Phase I | TAK-500 Pembrolizumab + TAK-500 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05071053 | Phase II | Ramucirumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (CARMEN-GC01) | Active, not recruiting | TUR | ESP | BEL | 3 |
NCT05101070 | Phase Ib/II | Pembrolizumab + S-531011 Pembrolizumab S-531011 | S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001) | Recruiting | USA | 1 |
NCT05102214 | Phase Ib/II | HLX301 | HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Recruiting | AUS | 0 |
NCT05109442 | Phase Ib/II | AFM24 + Atezolizumab | Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers | Recruiting | USA | POL | GBR | ESP | 1 |
NCT05111626 | Phase I | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Bemarituzumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102) | Active, not recruiting | USA | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 10 |
NCT05128487 | Phase Ib/II | NDI-101150 NDI-101150 + Pembrolizumab | A Study of NDI 1150-101 in Patients With Solid Tumors | Active, not recruiting | USA | 0 |
NCT05135845 | Phase II | Capmatinib + Spartalizumab | Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST) | Suspended | FRA | 0 |
NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
NCT05152147 | Phase III | Capecitabine + Oxaliplatin + Trastuzumab Capecitabine + Oxaliplatin + ZW25 Cisplatin + Fluorouracil + Trastuzumab Cisplatin + Fluorouracil + ZW25 Cisplatin + Fluorouracil + Tislelizumab + ZW25 Capecitabine + Oxaliplatin + Tislelizumab + ZW25 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01) | Recruiting | TUR | ROU | POL | NLD | ITA | IRL | GRC | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 16 |
NCT05153304 | Phase Ib/II | Ipilimumab + Nivolumab | A Phase I/II Study of Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers | Withdrawn | USA | 0 |
NCT05177133 | Phase II | Capecitabine + Oxaliplatin + Retifanlimab | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus) (AuspiCiOus) | Recruiting | NLD | 0 |
NCT05187182 | Phase I | CA-4948 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CA-4948 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer | Recruiting | USA | 0 |
NCT05190445 | Phase II | PRS-343 + Tucatinib Paclitaxel + PRS-343 + Ramucirumab | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | Active, not recruiting | USA | 1 |
NCT05205330 | Phase Ib/II | Balstilimab + CR6086 | CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers | Recruiting | ITA | 0 |
NCT05207722 | Phase Ib/II | Aldesleukin + CYNK-101 + Pembrolizumab + Trastuzumab | CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT05221320 | Phase II | Hydroxychloroquine + Ulixertinib | Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies | Terminated | USA | 0 |
NCT05269381 | Phase I | Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) | Recruiting | USA | 0 |
NCT05274048 | Phase I | Neratinib + Trastuzumab deruxtecan | Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | Recruiting | USA | 0 |
NCT05311176 | Phase II | IMU-131 + Paclitaxel + Ramucirumab IMU-131 + Pembrolizumab | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON) | Completed | AUS | 1 |
NCT05329766 | Phase II | AB680 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Zimberelimab Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric) | Recruiting | USA | FRA | CAN | 3 |
NCT05365581 | Phase I | ASP2138 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin ASP2138 + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab ASP2138 + Paclitaxel + Ramucirumab ASP2138 | A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Recruiting | USA | ITA | FRA | 3 |
NCT05379972 | Phase II | Olaparib + Pembrolizumab | Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers | Recruiting | USA | 0 |
NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | Recruiting | AUS | 1 |
NCT05417321 | Phase Ib/II | HB0036 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05427487 | Phase I | IVX037 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT05429762 | Phase I | SAR408701 | Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (TusaRav-QT) | Terminated | USA | TUR | FRA | ESP | BEL | 0 |
NCT05458219 | Phase I | IBI343 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | AUS | 1 |
NCT05476796 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Nivolumab + Oxaliplatin + Trifluridine-tipiracil hydrochloride Oxaliplatin + Trifluridine-tipiracil hydrochloride Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer (LOGICAN) | Recruiting | FRA | 0 |
NCT05482516 | Phase III | Atezolizumab + Bevacizumab | Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI) | Recruiting | USA | 0 |
NCT05482893 | Phase I | PT886 | PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) | Recruiting | USA | 0 |
NCT05504720 | Phase II | Pembrolizumab + Trastuzumab Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab | Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma | Active, not recruiting | DEU | 0 |
NCT05525286 | Phase Ib/II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin + SOT102 Gemcitabine + Nab-paclitaxel + SOT102 SOT102 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01) | Recruiting | USA | FRA | ESP | CZE | BEL | 0 |
NCT05539430 | Phase I | LB1908 | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma | Recruiting | USA | 0 |
NCT05555251 | Phase Ib/II | BI-1607 + Trastuzumab | BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST) | Active, not recruiting | GBR | ESP | DEU | 0 |
NCT05568095 | Phase III | AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab AB154 + Capecitabine + Oxaliplatin + Zimberelimab Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221) | Active, not recruiting | USA | TUR | ROU | POL | LTU | ITA | ISR | HUN | GRC | GBR | FRA | ESP | CAN | BRA | AUS | ARG | 13 |
NCT05614102 | Phase I | BAY2965501 | A First-in-human Study to Learn How Safe the Study Treatment BAY2965501 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | ESP | BEL | 3 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05702229 | Phase II | AZD2936 + Fluorouracil + Leucovorin + Oxaliplatin AZD2936 + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + MEDI5752 + Oxaliplatin Capecitabine + MEDI5752 + Oxaliplatin | Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | USA | GBR | ESP | 4 |
NCT05802056 | Phase I | Aldesleukin + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | Aldesleukin in Combination With Nivolumab and Standard Chemotherapy for the Treatment of Gastric Cancer With Peritoneal Metastasis, CONTROL Study | Recruiting | USA | 0 |
NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 1 |
NCT05836584 | Phase II | Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab Atezolizumab + Capecitabine + Oxaliplatin | Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer | Recruiting | USA | 0 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05859477 | Phase II | Capecitabine + Nivolumab + Oxaliplatin | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer (NIVOFGFR2) | Recruiting | USA | 0 |
NCT05862324 | Phase Ib/II | TAC01-CLDN18.2 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) | Recruiting | USA | CAN | 0 |
NCT05902988 | Phase Ib/II | VLS-1488 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Recruiting | USA | 0 |
NCT05965479 | Phase II | Trastuzumab deruxtecan | Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER) | Recruiting | GBR | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT06005493 | Phase Ib/II | AZD5863 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | NLD | GBR | FRA | 4 |
NCT06038578 | Phase II | Paclitaxel + Ramucirumab + TRK-950 Paclitaxel + Ramucirumab | A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | Recruiting | USA | 2 |
NCT06043427 | Phase II | Paclitaxel + Ramucirumab Paclitaxel + Ramucirumab + ZW25 | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | Recruiting | CAN | 0 |
NCT06048081 | Expanded access | Fluorouracil + Leucovorin + Oxaliplatin + Zolbetuximab Capecitabine + Oxaliplatin + Zolbetuximab | Early Access Program for Zolbetuximab | Available | USA | DEU | 0 |
NCT06055439 | Phase Ib/II | CHM-2101 CAR-T cells | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | Recruiting | USA | 0 |
NCT06056024 | Phase I | BI 3706674 | A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus | Recruiting | USA | 3 |
NCT06059495 | Phase II | Dostarlimab-gxly | Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (DEWI) | Recruiting | FRA | 0 |
NCT06109467 | Phase II | Fluorouracil + Leucovorin + Neratinib + Oxaliplatin + Pembrolizumab + Trastuzumab | Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT06116136 | Phase Ib/II | Pembrolizumab + S095029 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. | Recruiting | USA | ITA | HUN | FRA | ESP | DNK | BEL | AUT | AUS | 0 |
NCT06123338 | Phase II | Pembrolizumab + Trastuzumab | A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer | Recruiting | USA | 0 |
NCT06157892 | Phase Ib/II | Disitamab vedotin + Tucatinib Disitamab vedotin | A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06203600 | Phase II | Paclitaxel + Ramucirumab Nivolumab + Paclitaxel + Ramucirumab | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Recruiting | USA | 0 |
NCT06219941 | Phase II | AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Recruiting | USA | POL | GBR | ESP | CAN | AUS | 7 |
NCT06244485 | Phase I | DS-3201b + Trastuzumab deruxtecan Datopotamab deruxtecan + DS-3201b | A Study of Valemetostat in Combination With DXd ADCs in Subjects With Solid Tumors | Recruiting | USA | 1 |
NCT06251973 | Phase II | AgenT-797 + Balstilimab + Botensilimab + Paclitaxel + Ramucirumab | A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | Recruiting | USA | 0 |
NCT06253650 | Phase II | Capecitabine + Trastuzumab deruxtecan Fluorouracil + Trastuzumab deruxtecan Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease (TRINITY) | Recruiting | ITA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06324357 | Phase Ib/II | Ado-trastuzumab emtansine + Zongertinib Trastuzumab deruxtecan + Zongertinib | Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT06330064 | Phase II | Ifinatamab deruxtecan | A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Recruiting | USA | TUR | POL | NLD | ITA | IRL | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 5 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06340711 | Phase II | OBP-301 + Pembrolizumab | Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Recruiting | USA | 0 |
NCT06346197 | Phase III | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin Capecitabine + Nivolumab + Oxaliplatin Balstilimab + Botensilimab | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (CIME) | Not yet recruiting | FRA | 0 |
NCT06346392 | Phase III | Rivoceranib Trifluridine-tipiracil hydrochloride Paclitaxel + Ramucirumab Docetaxel Paclitaxel Irinotecan AZD0901 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CHE | CAN | 8 |
NCT06356311 | Phase III | Trifluridine-tipiracil hydrochloride Irinotecan Paclitaxel Docetaxel SKB264 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Recruiting | USA | POL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 9 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06445972 | Phase Ib/II | Paclitaxel + Ramucirumab Paclitaxel + SKB264 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Recruiting | USA | NOR | ITA | FRA | DEU | CHE | 4 |
NCT06544655 | Phase I | BMS-986484 + Nivolumab BMS-986484 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT06675136 | Phase I | Nab-paclitaxel + Paclitaxel + Ramucirumab | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | Not yet recruiting | USA | 0 |
NCT06680622 | Phase II | Bemarituzumab + Paclitaxel + Ramucirumab Bemarituzumab + Trifluridine-tipiracil hydrochloride Bemarituzumab + Irinotecan | Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy | Not yet recruiting | DEU | 0 |
NCT06697197 | Phase Ib/II | BMS-986482 + Nivolumab and relatlimab-rmbw Bevacizumab + BMS-986482 BMS-986482 BMS-986298 + BMS-986482 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Not yet recruiting | USA | 0 |